Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | EVP, Scientific Strategy & CSO | December 15, 2022 | December 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date December 15, 2022 · Filed December 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 430,958 |
Reported balance
After 2022-12-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-12-15 · Exercise / conversion · Acquired 20,000 · Balance 430,958 F1: Includes 120,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| Common StockSEC Table I · non-derivative | Direct | 410,958 |
Reported balance
After 2022-12-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-12-15 · Sale · Disposed 20,000 · Balance 410,958 F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022. F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.71 to $16.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2023-02-10 | Direct | 20,000 |
Reported balance
After 2022-12-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-15 · Exercise / conversion · Disposed 20,000 · Balance 20,000 F5: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 17,105 |
Reported balance
Holding disclosure · report date 2022-12-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 17,105 F4: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of December 14, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 120,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.
F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.71 to $16.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of December 14, 2022.
F5: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2022 Filed Dec 17, 2022 01:09 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000939767-22-000122 · wf-form4_167123936903484.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:09 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 20,000 | $15.88 | $317,600.00 |
DisclosureSEC source: 0000939767-22-000122 · wf-form4_167123936903484.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,958 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.71 to $16.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:09 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 20,000 | $4.20 | $84,000.00 |
DisclosureSEC source: 0000939767-22-000122 · wf-form4_167123936903484.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 120,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2022 Filed Nov 18, 2022 01:42 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,177 | $16.71 | $119,927.67 |
DisclosureSEC source: 0000939767-22-000113 · wf-form4_166873573294104.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,958 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 11, 2020, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on September 30, 2021. F2 · balance_after: Includes 120,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 03, 2022 Filed Aug 6, 2022 01:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,177 | $21.49 | $154,233.73 |
DisclosureSEC source: 0000939767-22-000087 · wf-form4_165975033940250.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,135 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 6, 2022 01:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 28,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000087 · wf-form4_165975033940250.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,312 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 57,900 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement of certain performance criteria as certified by the Compensation Committee (the "Committee"); and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F3 · shares: On August 3, 2022, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on August 15, 2023, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024. F4 · balance_after: Includes 134,858 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 15, 2022 Filed May 18, 2022 00:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 6,123 | $20.08 | $122,949.84 |
DisclosureSEC source: 0000939767-22-000061 · wf-form4_165283331491227.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,362 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2021. F2 · balance_after: Includes 120,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:52 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 59,490 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000035 · wf-form4_164679071956142.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,485 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2023 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 132,731 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:09 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 17,651 | $18.59 | $328,132.09 |
DisclosureSEC source: 0000939767-22-000021 · wf-form4_164514655521783.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,995 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:09 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,526 | $18.59 | $46,958.34 |
DisclosureSEC source: 0000939767-22-000021 · wf-form4_164514655521783.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,646 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. F2 · balance_after: Includes 73,241 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 47,500 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0000939767-21-000115 · wf-form4_163979129617804.xml · derivative · entry 6 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,500 shares Expires 2022-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option, representing the right to purchase a total of 190,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 47,500 | $17.44 | $828,400.00 |
DisclosureSEC source: 0000939767-21-000115 · wf-form4_163979129617804.xml · nonDerivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,172 F6 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021. F7 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.95 to $17.86. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 7 to this Form 4. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 47,500 | $6.21 | $294,975.00 |
DisclosureSEC source: 0000939767-21-000115 · wf-form4_163979129617804.xml · nonDerivative · entry 3 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 4,646 | $17.00 | $78,982.00 |
DisclosureSEC source: 0000939767-21-000115 · wf-form4_163979129617804.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,172 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 15, 2021. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 18,741 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000115 · wf-form4_163979129617804.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,818 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 18,741 shares of common stock. The PSU award generally vests as follows: (i) 50% of the original number of shares subject to the award vest upon certification by the Compensation Committee (the "Committee") that Exelixis, Inc. has achieved certain performance criteria related to the submission of Investigational New Drug applications with the U.S. Food and Drug Administration, or equivalent applications or filings with a foreign governmental authority, with respect to product candidates discovered, in-licensed or acquired by Exelixis, Inc. (the "2018 PSU Goal"); and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On December 15, 2021, the Committee convened to determine that the 2018 PSU Goal had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2023, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 113,573 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 47,500 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · derivative · entry 7 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2022-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option, representing the right to purchase a total of 190,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 53,022 | $18.10 | $959,698.20 |
DisclosureSEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · nonDerivative · entry 5 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,077 F6 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on October 22, 2020. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,323 | $18.10 | $42,046.30 |
DisclosureSEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · nonDerivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,099 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 2, 2020. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 6,818 | $18.10 | $123,405.80 |
DisclosureSEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · nonDerivative · entry 3 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,422 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 47,500 | $18.09 | $859,275.00 |
DisclosureSEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,240 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.94 to $18.28. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 47,500 | $6.21 | $294,975.00 |
DisclosureSEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 104,202 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 15, 2021 Filed Oct 16, 2021 00:15 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 47,500 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0000939767-21-000089 · wf-form4_163434332005821.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 47,500 shares Expires 2022-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 190,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019. Read SEC document |
| October 15, 2021 Filed Oct 16, 2021 00:15 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 47,500 | $21.92 | $1,041,200.00 |
DisclosureSEC source: 0000939767-21-000089 · wf-form4_163434332005821.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,240 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.69 to $22.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| October 15, 2021 Filed Oct 16, 2021 00:15 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 47,500 | $6.21 | $294,975.00 |
DisclosureSEC source: 0000939767-21-000089 · wf-form4_163434332005821.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 229,577 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 30, 2021 Filed Oct 5, 2021 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,177 | $20.63 | $148,061.51 |
DisclosureSEC source: 0000939767-21-000084 · wf-form4_163339215355376.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,240 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 30, 2021. Read SEC document |
| September 30, 2021 Filed Oct 5, 2021 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 28,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000084 · wf-form4_163339215355376.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,417 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 57,900 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F3 · shares: On September 30, 2021, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on November 15, 2022, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024. F4 · balance_after: Includes 229,577 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 23:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 47,500 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0000939767-21-000081 · wf-form4_163192296573118.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,500 Underlying: Common Stock · 47,500 shares Expires 2022-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 190,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 23:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 47,500 | $20.46 | $971,850.00 |
DisclosureSEC source: 0000939767-21-000081 · wf-form4_163192296573118.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,467 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.62. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 23:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 47,500 | $6.21 | $294,975.00 |
DisclosureSEC source: 0000939767-21-000081 · wf-form4_163192296573118.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 23:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-21-000079 · wf-form4_162933099603526.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 175,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 23:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 55,000 | $18.44 | $1,014,200.00 |
DisclosureSEC source: 0000939767-21-000079 · wf-form4_162933099603526.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,467 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.22 to $18.65. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 23:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 55,000 | $1.90 | $104,500.00 |
DisclosureSEC source: 0000939767-21-000079 · wf-form4_162933099603526.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-21-000072 · wf-form4_162647991700323.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 60,000 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 175,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 60,000 | $17.47 | $1,048,200.00 |
DisclosureSEC source: 0000939767-21-000072 · wf-form4_162647991700323.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,467 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.22 to $17.63. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 60,000 | $1.90 | $114,000.00 |
DisclosureSEC source: 0000939767-21-000072 · wf-form4_162647991700323.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 17, 2021 Filed Jun 23, 2021 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-21-000070 · wf-form4_162440660264370.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 60,000 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 175,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| June 17, 2021 Filed Jun 23, 2021 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 60,000 | $22.18 | $1,330,800.00 |
DisclosureSEC source: 0000939767-21-000070 · wf-form4_162440660264370.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,467 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.90 to $22.40. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| June 17, 2021 Filed Jun 23, 2021 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 60,000 | $1.90 | $114,000.00 |
DisclosureSEC source: 0000939767-21-000070 · wf-form4_162440660264370.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 23:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-21-000040 · wf-form4_161740743547342.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 23:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 60,000 | $22.96 | $1,377,600.00 |
DisclosureSEC source: 0000939767-21-000040 · wf-form4_161740743547342.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,467 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2020. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.58 to $23.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 23:51 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 60,000 | $1.70 | $102,000.00 |
DisclosureSEC source: 0000939767-21-000040 · wf-form4_161740743547342.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2021 Filed Mar 6, 2021 00:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 49,395 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000031 · wf-form4_161499218634349.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,467 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2022 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:49 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-21-000029 · wf-form4_161481892190996.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 65,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:49 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 65,000 | $22.11 | $1,437,150.00 |
DisclosureSEC source: 0000939767-21-000029 · wf-form4_161481892190996.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,072 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2020. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.65 to $22.45. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:49 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 65,000 | $1.70 | $110,500.00 |
DisclosureSEC source: 0000939767-21-000029 · wf-form4_161481892190996.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 165,707 be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 01:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 3,718 | $21.91 | $81,461.38 |
DisclosureSEC source: 0000939767-21-000015 · wf-form4_161361029561533.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,072 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on December 4, 2019. F2 · balance_after: Includes 165,707 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 19,997 | $22.56 | $451,132.32 |
DisclosureSEC source: 0000939767-21-000012 · wf-form4_161257791484447.xml · nonDerivative · entry 3 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,790 F8 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on February 3, 2021. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 71,293 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000012 · wf-form4_161257791484447.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,787 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F5 · date: On September 20, 2019, the Reporting Person was granted a PSU award the under 2017 Equity Incentive Plan covering 142,586 shares of common stock (such award, the "2019 Award," and such shares, the "Target Shares"). The 2019 Award generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement certain performance criteria as certified by Committee; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the 2019 Award provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the 2019 Award. F6 · shares: On February 3, 2021, the Committee determined the maximum performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 200% of the Target Shares subject to the 2019 Award. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and the remaining 25% of the Target Shares will vest on February 15, 2022, subject to the Reporting Person's continuous service through that date. F7 · balance_after: Includes 173,204 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 9,370 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000012 · wf-form4_161257791484447.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,494 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 9,370 shares of common stock (such award, the "2018 Award"). The 2018 Award generally vests as follows: (i) 50% of the original number of shares subject to the 2018 Award vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria related to clinical trial enrollment or positive top-line results (the "2018 Goal"); and (ii) 50% of the original number of shares subject to the 2018 Award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On February 3, 2021, the Committee convened to determine that the 2018 Goal had been achieved, resulting in the immediate vesting of 50% of the 2018 Award, and the remaining 50% will vest on February 15, 2022, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 137,557 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-21-000007 · wf-form4_161240023597689.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 65,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.